---
layout: post
title: "S12 Nonclinical Biodistribution Considerations for Gene Therapy Products; International Council for Harmonisation; Guidance for Industry; Availability"
date: 2026-02-05 18:55:23 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-09179
original_published: 2023-05-01 00:00:00 +0000
significance: 8.00
---

# S12 Nonclinical Biodistribution Considerations for Gene Therapy Products; International Council for Harmonisation; Guidance for Industry; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** May 01, 2023 00:00 UTC
**Document Number:** 2023-09179

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "S12 Nonclinical Biodistribution Considerations for Gene Therapy Products." The guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The final guidance provides harmonized recommendations for the conduct and overall design of nonclinical biodistribution (BD) studies for gene therapy (GT) products. The recommendations in the guidance endeavor to facilitate the development of investigational GT products, while avoiding unnecessary use of animals, in accordance with the 3Rs (reduce/refine/replace) principles. The final guidance replaces the draft guidance entitled "S12 Nonclinical Biodistribution Considerations for Gene Therapy Products" issued on September 9, 2021.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/05/01/2023-09179/s12-nonclinical-biodistribution-considerations-for-gene-therapy-products-international-council-for)
- API: https://www.federalregister.gov/api/v1/documents/2023-09179

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
